AGP Executive Report
Last update: 30 minutes agoPrison Health Policy Clash: The Trump administration asked the U.S. Supreme Court to allow restrictions on transgender medical care for people in federal prisons, setting up another high-stakes legal fight. In-Custody Death: A 62-year-old San Diego Central Jail inmate died after going into medical distress at the facility clinic; investigators and the Medical Examiner will determine cause and manner. Drug Access Gap: A new report says more than half of U.S.-approved drugs from 2021–2025 still aren’t available in Japan, leaving cancer and rare-disease patients waiting. FDA Approvals & Biosimilars: Azurity won FDA approval for Lamlique (lamotrigine) oral suspension, while Teva’s DEGEVMA (denosumab-adet) gained approval as a biosimilar to Xgeva. Behavioral Health Funding Pressure: Oregon faces an estimated $1.2B behavioral health cut over four years, raising fears of longer waits and reduced access. Myeloma Research: At IMS 2026, multiple updates highlighted MRD-guided strategies and new therapies, including etentamig data and MRD-negative response gains with iberdomide-based regimens. Medicare Enrollment Reminder: Open enrollment starts Oct. 15, with guidance urging retirees to compare plans and watch IRMAA impacts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
